ArticleDrug design, development and therapy2026
The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Comparative Evidence for Telitacicept, Glucocorticoids, and Nefecon in IgA Nephropathy: Clinical Value and Interpretive Considerations [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IgA nephropathy (IgAN) is one of the leading causes of end-stage renal disease (ESRD). Telitacicept has been demonstrated significant efficacy in IgAN, but its comparative efficacy versus the recommended regimens in the 2025 KDIGO guideline remains unclear. The aim of this study was to investigate the clinical efficacy and safety of glucocorticoids, telitacicept, and nefecon Methods: We recruited 101 patients with IgAN confirmed by renal biopsy. The patients were categorized into three groups according to the treatment they received: the GC group, the Telitacicept group, and the Nefecon group. Treatment responses, including complete remission (CR) and partial remission (PR), and adverse events were compared among the three groups after 9 months of follow-up. Results: At the 9-month follow-up, the CR rates were 93.5%, 86.2%, and 70.7% for the GC group, Telitacicept group, and Nefecon group, respectively ( Conclusion: Our study confirmed that glucocorticoids have superior efficacy to nefecon, but are associated with a higher incidence of adverse events. Telitacicept offered both efficacy and safety, and can be recommended for high-risk IgAN patients who are intolerant to glucocorticoids.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.